PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.

Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Annual Meeting held in Chicago, USA, from May 30 to June 3, the results of the Phase Ib/II clinical study of 9MW2821 in combination with Toripalimab for the treatment of patients with ...

Paste Magazine is your source for the best music, movies, TV, comedy, videogames, books, comics, craft beer, politics and ...